Back to top
more

Cresco Labs Inc. (CRLBF)

(Delayed Data from OTC)

$2.10 USD

2.10
281,056

-0.09 (-4.11%)

Updated Apr 18, 2024 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CRLBF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Cresco Labs Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 109 122 226 141 54
Receivables 52 57 45 32 17
Notes Receivable 0 0 0 0 0
Inventories 108 135 137 183 81
Other Current Assets 9 13 14 7 7
Total Current Assets 278 326 422 362 159
Net Property & Equipment 368 380 369 195 156
Investments & Advances 1 1 6 4 1
Other Non-Current Assets 1 1 1 21 19
Deferred Charges 12 0 7 7 2
Intangibles 577 738 884 647 232
Deposits & Other Assets 4 9 4 4 1
Total Assets 1,358 1,584 1,780 1,333 617
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 28 28 32 86 63
Current Portion Long-Term Debt 12 19 20 15 0
Current Portion Capital Leases 9 26 21 25 12
Accrued Expenses 69 65 95 0 0
Income Taxes Payable 82 95 47 49 15
Other Current Liabilities 0 48 73 19 60
Total Current Liabilities 200 281 288 195 150
Mortgages 0 0 0 0 0
Deferred Taxes/Income 47 83 103 60 45
Convertible Debt 0 0 0 0 0
Long-Term Debt 498 469 465 169 1
Non-Current Capital Leases 164 156 119 145 83
Other Non-Current Liabilities 22 7 7 39 15
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 930 996 983 608 294
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1,689 1,705 1,598 826 276
Capital Surplus 83 0 0 35 26
Retained Earnings -1,266 -1,076 -842 -286 -115
Other Equity -79 -41 42 150 136
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 428 588 798 725 323
Total Liabilities & Shareholder's Equity 1,358 1,584 1,780 1,333 617
Total Common Equity 428 588 798 725 323
Shares Outstanding 345.60 345.60 271.50 NA NA
Book Value Per Share 1.24 1.70 2.94 -0.01 0.00

Fiscal Year End for Cresco Labs Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 109 113 75 90
Receivables NA 52 59 59 50
Notes Receivable NA 0 0 0 0
Inventories NA 108 115 121 135
Other Current Assets NA 9 17 10 11
Total Current Assets NA 278 303 265 286
Net Property & Equipment NA 368 383 388 391
Investments & Advances NA 1 1 1 1
Other Non-Current Assets NA 1 1 1 1
Deferred Charges NA 12 9 16 0
Intangibles NA 577 578 713 737
Deposits & Other Assets NA 4 4 5 10
Total Assets NA 1,358 1,399 1,511 1,551
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 28 20 20 20
Current Portion Long-Term Debt NA 12 28 18 28
Current Portion Capital Leases NA 9 25 26 26
Accrued Expenses NA 69 76 78 77
Income Taxes Payable NA 82 111 92 80
Other Current Liabilities NA 0 1 2 41
Total Current Liabilities NA 200 261 238 273
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 47 52 82 80
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 498 491 472 471
Non-Current Capital Leases NA 164 149 150 152
Other Non-Current Liabilities NA 21 23 7
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 930 973 964 983
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1,689 1,778 1,779 1,728
Capital Surplus NA 83 0 0 0
Retained Earnings NA -1,266 -1,271 -1,154 -1,106
Other Equity NA -79 -82 -78 -55
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 428 426 547 567
Total Liabilities & Shareholder's Equity NA 1,358 1,399 1,511 1,551
Total Common Equity 0 428 426 547 567
Shares Outstanding 345.60 345.60 345.60 345.60 345.60
Book Value Per Share 0.00 1.24 1.23 1.58 1.64